Since the introduction of somatostatin receptor (sst) imaging using 123I-Tyr3-octreotide [1], peptide receptor imaging and radiotherapy (PRRT) has become an established modality in the management of neuroendocrine tumours (NET) [2].
Based on the findings of a previous study [3] investigating metal-labelled DOTA-octreotides substituted at Tyr3, we hypothesized that derivatives of DOTA-iodo-Tyr3-octreotide might be excellent candidates for sstr imaging and therapy. Consequently, we evaluated 68Ga-DOTA-iodoTyr3-octreotate (68Ga-HA-DOTATATE; HA, high affinity) in vitro and in a preliminary PET study. As hypothesized, 68Ga-HA-DOTATATE showed high affinity for human sst2,5 as well as diagnostic and logistical advantages, i.e. unlimited precursor availability. The (Leu8,D-Trp22, [125I]Tyr25)-SST28 IC50 values (in nanomoles) for Ga-HA-DOTATATE were >10.000 (sst1), 0.64 ± 0.23 (sst2), >1,000 (sst3 and sst4) and 59.7 ± 15.1 (sst5), and for Ga-DOTATATE were >10,000 (sst1), 0.67 ± 0.25 (sst2), >1.000 (sst3), 822 ± 327 (sst4) and >1,000 (sst5).
In a first PET study a 73-year-old patient suffering from a NET with unknown primary and liver metastases was investigated with 68Ga-HA-DOTATATE and 68Ga-DOTATATE. Both agents showed a possible small primary tumour in the midgut and five liver metastases that showed somewhat higher 68Ga-HA-DOTATATE uptake (mean SUVmax 23.8 vs. 21.6). The visual detectability of three small liver metastases with low uptake was superior with 68Ga-HA-DOTATATE.
In summary, 68Ga-HA-DOTATATE provides high-quality images comparable to or better than those with 68Ga-DOTATATE. Further clinical studies are needed to confirm these first results and explore the use of HA-DOTATATE agents for PRRT.
References
Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242–4.
Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Horsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.
Ginj M, Schmitt JS, Chen J, Waser B, Reubi JC, de Jong M, et al. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol. 2006;13:1081–90.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brogsitter, C., Schottelius, M., Zöphel, K. et al. Twins in spirit: DOTATATE and high-affinity DOTATATE. Eur J Nucl Med Mol Imaging 40, 1789 (2013). https://doi.org/10.1007/s00259-013-2497-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-013-2497-5